Latest Plexxikon Stories

2011-02-28 17:30:00


2010-08-26 14:00:17

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas.

2010-06-15 15:45:30

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma

2009-06-03 10:38:53

An early-stage clinical trial of a new cancer drug could lead to the creation of effective melanoma drugs, researchers at a meeting in Orlando, Fla.,said. The Wall Street Journal said Wednesday the study presented at the American Society of Clinical Oncology's annual meeting showed a drug called PLX4032 was effectively used to shrink tumors in nine of 16 study patients.

2008-10-03 09:00:37


2008-09-04 09:00:08

US-based drug discovery and development company Plexxikon has started a Phase I human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs pain as well as polycystic kidney disease.

2008-08-06 18:00:38

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit.

Word of the Day
  • A political dynamiter.
The word 'dynamitard' is related to 'dynamite', which comes from a Greek root meaning 'power' and was coined by Alfred Nobel.